Table 2-. Timing of plasma sample acquisition identifies new mutations.

To determine if multiple plasma samples over time could identify previously missed tumor mutations, tumor samples in Patient #9 collected at autopsy were compared to near autopsy mutations, and vice versa. Nucleotide changes are shown, with notations for synonymous (s), missense (m), or UTR variants (u).

Patient	Sample	Concordant Mutations Newly Identified
9	Lymph Node Met	AKT3 c.*461A>G (u), ERBB3 c.3348G>A (s),
		HNF1A c.1741A>G (m), FGFR4 c.1162G>A (m)
	Omental Met	RET c.135A>G (s), ALK c.702T>A (s),
		FGFR4 c.1162G>A (m), SDK1 c.*5301G>A (u)
	Ovarian Met	BRCA1 c.4900A>G (m), FGFR4 c.1162G>A (m), NOTCH1
		c.6555C>T (s)
9A	Heart Met	TSC2 c.5202T>C (s)
	Left Kidney Met	None
	Right Kidney Met	SRC c.1218G>C (s)
	Liver 1 Met	None
	Liver 2 Met	None
	Omental 1 Met	None